Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in...
Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion
VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ -- WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the neuromodulation device designed by WAT for weight and health management. The study revealed that electroacupuncture may help improve exercise performance and post-exercise recovery by reducing heart rate and perceived exertion during physical activity. Published in...
ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug...
Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine
- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine- Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ -- Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for...
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, has administered the first dose to a patient in an investigator-initiated trial...
CBC Group’s R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion
- R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer early detection solutions in new markets - Transaction underscores R-Bridge's commitment to advancing life sciences innovations and expanding access to high-quality medical care SINGAPORE, Jan. 13, 2025 /PRNewswire/ -- CBC Group's R-Bridge Healthcare Fund ("R-Bridge") announces a US$40 million structured financing transaction with Mirxes Pte Ltd., a Singapore-based miRNA technology company specializing in cancer...
XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut
NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut. The facility includes a clinic to recruit and evaluate participants for clinical research studies,...
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024). Sustained revenue growth Q4 2024 unaudited revenue of approximately US$142 million (AU$218 million), represents...
Scintimun® Commercialization Partnership with Curium Pharma
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic radiopharmaceutical used for infection imaging....
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successfully raised over US$70 million in Series C financing led by EQT with participation from Qiming Venture Partners,...
